<DOC>
	<DOC>NCT00391391</DOC>
	<brief_summary>Primary Objective: To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. Secondary Objectives: - To describe the immunogenicity of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. - To describe the safety of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years.</brief_summary>
	<brief_title>Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 6 months to 8 years but not yet 9 years on the day of inclusion. Subject is healthy, as determined by medical history. Institution Review Board (IRB)approved informed assent form signed by eligible subject (if required by local regulations) and/or an IRBapproved informed consent form signed by the subject's parent(s) or legal representative (and by an independent witness if required by local regulations). Parent or legal guardian willing and able to attend (bring subject) to all scheduled visits and comply with all trial procedures. Exclusion Criteria : Participation in another clinical trial in the 4 weeks preceding the trial vaccination. Planned participation in another clinical trial during the present trial period. Personal or family history of GuillainBarré Syndrome. Congenital or acquired immunodeficiency, immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months, or longterm systemic corticosteroid therapy injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting &lt; 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a vaccine containing the same substances. Chronic illness at a stage that could interfere with trial conduct or completion Received blood or bloodderived products in the previous 3 months. Any vaccination in the 4 weeks preceding or following the trial vaccinations (Subjects can take standard childhood vaccination(s) following Visit 3 blood draw). Known current human immunodeficiency virus (HIV), hepatitis B (HBsAg) or hepatitis C infection or seropositivity. Known thrombocytopenia or bleeding disorder contraindicating IM vaccination. Acute medical illness, with or without fever, within the last 72 hours or an oral temperature ≥ 37.5 °C (99.5 °F) or rectal temperature of ≥ 38°C (100.4 °F) at the time of enrollment. History of seizures. Received antibiotics therapy within 72 hours preceding the trial vaccination. Received any allergy shots in the 7day period preceding trial vaccination and/or scheduled to receive any allergy shots in the 7day period after trial vaccination. Any condition, which in the opinion of the investigator would pose a health risk to the participant.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Inactivated Split-virion influenza vaccine</keyword>
	<keyword>Infants</keyword>
	<keyword>children.</keyword>
</DOC>